Sixty-seven patients with complicated urinary tract infections were randomized in double-blind fashion to ceftazidime or moxalactam (MOX) of resistance in Pseudomonas aeruginosa during therapy with MOX has been reported (11). Therefore, a Pseudomonas isolate signalled the pharmacist to increase the dose to 2 g every 12 h for patients randomized to MOX. The usual length of treatment was 7 days. Four patients were treated for 9.5, 10, 10, and 11.5 days, respectively. One patient had pyelonephritis; the others had therapy extended through the performance of cystoscopy.
Ceftazidime (CAZ) is a new 2-aminothiazolyl cephalosporin which has activity against a broad spectrum of both gram-positive and gram-negative organisms (4, 6) . It has shown particular promise in the treatment of various Pseudomonas species, especially Pseudomonas aeruginosa (8) . It is excreted unchanged by glomerular filtration and has a half-life of 1.8 h in patients with normal renal function (8) .
In this study, CAZ and moxalactam (MOX) were compared for safety and efficacy in the treatment of complicated urinary tract infections. Susceptibility patterns of posttherapy isolates were studied to detect the development of antimicrobial resistance emerging during therapy. In (Table 3) .
All patients had resolution of signs and symptoms while on therapy (Table 4) . No patients had persistence or superinfection during therapy. At 5 to 9 days posttherapy, the difference between cure rates (CAZ, 74%; MOX, 52%) was not statistically significant (P = 0.079). Differences in relapse rates (CAZ, 11%; MOX, 33%) were significant (P = 0.0497). CAZ treatment relapses were with Escherichia coli (two) and Citrobacter diversus (one). MOX treatment relapses were with E. coli (three), Klebsiella pneumoniae (two), Pseudomonas aeruginosa (two), Proteus mirabilis (one), and Serratia marcescens (one). Reinfecting isolates in the CAZ group were enterococci (three) and a Candida species (one). Reinfecting isolates in the MOX group were enterococci (four) and E. coli (one). CAZ had higher cure rates than MOX in both nosocomial (60 versus 38%) and community-acquired (92 versus 64%) infections, but these differences were not statistically significant.
One patient with Pseudomonas aeruginosa (not serotypable) treated with MOX became reinfected with a second strain of Pseudomonas aeruginosa (serotype 11) which was resistant to MOX, cefotaxime, ceftriaxone, carbenicillin, (9) . These infections contribute to patient mortality (10) and health-care costs (5) . MOX and CAZ compare favorably with aminoglycosides in this setting (2, 9) . In our study, CAZ produced higher cure and lower relapse rates than did MOX for infections due to urinary pathogens susceptible to both antibiotics. It also was effective for infections due to MOX-resistant Pseudomonas aeruginosa. Side effects were infrequent and have been reported previously with this class of antibiotics (7) .
The high relapse and reinfection rates likely relate to the irreversible urinary tract abnormalities of our study population. A longer course of therapy might have produced more cures (3).
The enterococcus was the most common reinfecting organism in both groups. This phenomenon has been seen previously with MOX (14) and the new monobactam antibiotic aztreonam (13) . The broad gram-negative enteric spectrum of these antibiotics presumably selects for this highly resistant family of gram-positive organisms. Of concern was the reinfection of one patient with a highly resistant Pseudomonas aeruginosa after MOX therapy. Microbial resistance after broad-spectrum antibiotic therapy is being reported with increased frequency (12) . Selective use of these agents should be based upon relevant advantages of clinically effective spectrum, toxicity, and cost.
